A phase 3, multicenter, prospective, randomized, double-blind study of two treatment regiments for candidemia and/or invasive candidiasis: Intravenous echinocandin followed by oral ibreafungerp versus intravenous echinocandin followed by fluconazole
Date:
07/01/2022
Topics:
Lead Investigators:
Summary
The primary objective of this study is to evaluate the efficacy of oral ibreafungerp as a step-down therapy, compared to oral fluconazole, in patients with candidemia and/or invasive candidiasis.